Molecular Diagnosis & Therapy

, Volume 22, Issue 3, pp 369–380 | Cite as

Novel Insights for Inhibiting Mutant Heterodimer IDH1wt-R132H in Cancer: An In-Silico Approach

  • Ezequiel Iván Juritz
  • Juan Pablo Bascur
  • Daniel Eduardo Almonacid
  • Fernando Danilo González-Nilo
Original Research Article



Isocitrate dehydrogenase 1 (IDH1) is a dimeric enzyme responsible for supplying the cell’s nicotinamide adenine dinucleotide phosphate (NADPH) reserves via dehydrogenation of isocitrate (ICT) and reduction of NADP+. Mutations in position R132 trigger cancer by enabling IDH1 to produce d-2-hydroxyglutarate (2-HG) and reduce inhibition by ICT. Mutant IDH1 can be found as a homodimer or a heterodimer.


We propose a novel strategy to inhibit IDH1 R132 variants as a means not to decrease the concentration of 2-HG but to provoke a cytotoxic effect, as the cell malignancy at this point no longer depends on 2-HG. We aim to inhibit the activity of the mutant heterodimer to block the wild-type subunit. Limiting the NADPH reserves in a cancerous cell will enhance its susceptibility to the oxidative stress provoked by chemotherapy.


We performed a virtual screening using all US FDA-approved drugs to replicate the loss of inhibition of mutant IDH1 by ICT. We characterized our results based on molecular interactions and correlated them with the described phenotypes.


We replicated the loss of inhibition by ICT in mutant IDH1. We identified 20 drugs with the potential to inhibit the heterodimeric isoform. Six of them are used in cancer treatment.


We present 20 FDA-approved drugs with the potential to inhibit IDH1 wild-type activity in mutated cells. We believe this work may provide important insights into current and new approaches to dealing with IDH1 mutations. In addition, it may be used as a basis for additional studies centered on drugs presenting differential sensitivities to different IDH1 isoforms.



The authors wish to thank Dr. Elisabeth Bik for her help improving the manuscript. FDGN thanks to Centro Interdisciplinario de Neurociencia de Valparaíso (CINV) which is a Millennium Institute supported by the Millennium Scientific Initiative of the Ministerio de Economía, Fomento y Turismo, Chile.

Compliance with Ethical Standards

Conflict of interest

The authors EIJ, JPB, DEA and FDGN have no conflicts of interest that are directly relevant to the content of this study. DEA is currently an employee of uBiome, Inc. and has received stock options as well as other compensations. FDGN is currently an advisor to uBiome, Inc. and has received stock options. uBiome had no influence on the design or execution of this study.


This study was funded by FONDECYT postdoctoral Grant no. 3150671 (PI: EIJ) and FONDECYT Proyecto de Inicio no. 11130578 (PI: DEA).


  1. 1.
    Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, Bardella C. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One. 2011;6(5):e19868. Scholar
  2. 2.
    Ma T, Peng Y, Huang W, Ding J. Molecular mechanism of the allosteric regulation of the αγ heterodimer of human NAD-dependent isocitrate dehydrogenase. Sci Rep. 2017;7:40921. Scholar
  3. 3.
    Reitman ZJ, Duncan CG, Poteet E, Winters A, Yan LJ, Gooden DM, Spasojevic I, Boros LG, Yang SH, Yan H. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutaratestimulate glutamine metabolism under hypoxia. J Biol Chem. 2014;289(34):23318–28. Scholar
  4. 4.
    Xie X, Baird D, Bowen K, Capka V, Chen J, Chenail G, Cho Y, Dooley J, Farsidjani A, Fortin P, Kohls D, Kulathila R, Lin F, McKay D, Rodrigues L, Sage D, Touré BB, van der Plas S, Wright K, Xu M, Yin H, Levell J, Pagliarini RA. Allosteric mutant IDH1 inhibitors reveal mechanisms for IDH1 mutant and isoform selectivity. Structure. 2017;25(3):506–13. Scholar
  5. 5.
    Cairns RA, Mak TW. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013;3(7):730–41. Scholar
  6. 6.
    Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. Scholar
  7. 7.
    Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008;116(6):597–602. Scholar
  8. 8.
    Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, Lee JY, Yoo NJ, Lee SH. Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer. 2009;125(2):353–5. Scholar
  9. 9.
    Yang B, Zhong C, Peng Y, Lai Z, Ding J. Molecular mechanisms of “off-on switch” of activities of human IDH1 by tumor-associated mutation R132H. Cell Res. 2010;20(11):1188–200. Scholar
  10. 10.
    Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabinowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson CB. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–34. Scholar
  11. 11.
    Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, Su SM. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–44. Scholar
  12. 12.
    Rajendran V. Structural analysis of oncogenic mutation of isocitrate dehydrogenase 1. Mol Biosyst. 2016;12(7):2276–87. Scholar
  13. 13.
    Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016;27(4):599–608. Scholar
  14. 14.
    DiNardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, Levine RL, Straley KS, Yen K, Patel JP, Agresta S, Abdel-Wahab O, Perl AE, Litzow MR, Rowe JM, Lazarus HM, Fernandez HF, Margolis DJ, Tallman MS, Luger SM, Carroll M. Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood. 2013;121(24):4917–24. Scholar
  15. 15.
    Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, Liu LX, Jiang WQ, Liu J, Zhang JY, Wang B, Frye S, Zhang Y, Xu YH, Lei QY, Guan KL, Zhao SM, Xiong Y. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17–30. Scholar
  16. 16.
    Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite d-2-hydroxyglutarate inhibits ALKBH DNA repair enzymes and sensitizes IDH mutant cells to alkylating agents. Cell Rep. 2015;13(11):2353–61. Scholar
  17. 17.
    Evans B, Griner E. Registered report: oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Elife. 2015;4:e07420. Scholar
  18. 18.
    Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836–52. Scholar
  19. 19.
    Suijker J, Oosting J, Koornneef A, Struys EA, Salomons GS, Schaap FG, Waaijer CJ, Wijers-Koster PM, Briaire-de Bruijn IH, Haazen L, Riester SM, Dudakovic A, Danen E, Cleton-Jansen AM, van Wijnen AJ, Bovée JV. Inhibition of mutant IDH1 decreases d-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines. Oncotarget. 2015;6(14):12505–19. Scholar
  20. 20.
    Gagné LM, Boulay K, Topisirovic I, Huot MÉ, Mallette FA. Oncogenic activities of IDH1/2 mutations: from epigenetics to cellular signaling. Trends Cell Biol. 2017;27(10):738–52. Scholar
  21. 21.
    Pietrak B, Zhao H, Qi H, Quinn C, Gao E, Boyer JG, Concha N, Brown K, Duraiswami C, Wooster R, Sweitzer S, Schwartz B. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of αHG. Biochemistry. 2011;50(21):4804–12. Scholar
  22. 22.
    Mu L, Xu W, Li Q, Ge H, Bao H, Xia S, Ji J, Jiang J, Song Y, Gao Q. IDH1 R132H mutation is accompanied with malignant progression of paired primary-recurrent astrocytic tumours. J Cancer. 2017;8(14):2704–12. Scholar
  23. 23.
    Upadhyay VA, Brunner AM, Fathi AT. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: progress and future directions. Pharmacol Ther. 2017;177:123–8. Scholar
  24. 24.
    Xu X, Zhao J, Xu Z, Peng B, Huang Q, Arnold E, Ding J. Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem. 2004;279(32):33946–57. Scholar
  25. 25.
    Duncan CG, Barwick BG, Jin G, Rago C, Kapoor-Vazirani P, Powell DR, Chi JT, Bigner DD, Vertino PM, Yan H. A heterozygous IDH1R132H/WT mutation induces genome-wide alterations in DNA methylation. Genome Res. 2012;22(12):2339–55. Scholar
  26. 26.
    Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it? Acta Neuropathol. 2013;125(5):621–36. Scholar
  27. 27.
    Lee WY, Chen KC, Chen HY, Chen CY. Potential mitochondrial isocitrate dehydrogenase R140Q mutant inhibitor from traditional Chinese medicine against cancers. Biomed Res Int. 2014;2014:364625. Scholar
  28. 28.
    Zheng M, Sun W, Gao S, Luan S, Li D, Chen R, Zhang Q, Chen L, Huang J, Li H. Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. Oncotarget. 2017;8(27):44255–65. Scholar
  29. 29.
    Han CH, Batchelor TT. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas. Chin Clin Oncol. 2017;6(3):33. Scholar
  30. 30.
    Birendra KC, DiNardo CD. Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk. 2016;16(8):460–5. Scholar
  31. 31.
    Stein EM. IDH2 inhibition in AML: finally progress? Best Pract Res Clin Haematol. 2015;28(2–3):112–5. Scholar
  32. 32.
    Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, Clark PM, Cloughesy TF, Letai A, Nathanson DA. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 2017;23(11):1342–51. Scholar
  33. 33.
    Kohanbash G, Carrera DA, Shrivastav S, Ahn BJ, Jahan N, Mazor T, Chheda ZS, Downey KM, Watchmaker PB, Beppler C, Warta R, Amankulor NA, Herold-Mende C, Costello JF, Okada H. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. J Clin Invest. 2017;127(4):1425–37. Scholar
  34. 34.
    Watanabe T, Nobusawa S, Kleihues P, Ohgaki H. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol. 2009;174(4):1149–53. Scholar
  35. 35.
    Brooks E, Wu X, Hanel A, Nguyen S, Wang J, Zhang JH, Harrison A, Zhang W. Identification and characterization of small-molecule inhibitors of the R132H/R132H mutant isocitrate dehydrogenase 1 homodimer and R132H/wild-type heterodimer. J Biomol Screen. 2014;19(8):1193–200. Scholar
  36. 36.
    Zheng B, Yao Y, Liu Z, Deng L, Anglin JL, Jiang H, Prasad BV, Song Y. Crystallographic investigation and selective inhibition of mutant isocitrate dehydrogenase. ACS Med Chem Lett. 2013;4(6):542–6. Scholar
  37. 37.
    Robinson GL, Philip B, Guthrie MR, Cox JE, Robinson JP, VanBrocklin MW, Holmen SL. In vitro visualization and characterization of wild type and mutant IDH homo- and heterodimers using bimolecular fluorescence complementation. Cancer Res Front. 2016;2(2):311–29. Scholar
  38. 38.
    Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, Thompson CB. The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem. 2013;288(6):3804–15. Scholar
  39. 39.
    Rajendran V, Gopalakrishnan C, Purohit R. Impact of point mutation P29S in RAC1 on tumorigenesis. Tumour Biol. 2016;37(11):15293–304.CrossRefPubMedGoogle Scholar
  40. 40.
    Rajendran V, Sethumadhavan R. Drug resistance mechanism of PncA in Mycobacterium tuberculosis. J Biomol Struct Dyn. 2014;32(2):209–21.CrossRefPubMedGoogle Scholar
  41. 41.
    Kamaraj B, Purohit R. Mutational analysis on membrane associated transporter protein (MATP) and their structural consequences in oculocutaeous albinism type 4 (OCA4)—a molecular dynamics approach. J Cell Biochem. 2016;117(11):2608–19.CrossRefPubMedGoogle Scholar
  42. 42.
    Kamaraj B, Gopalakrishnan C, Purohit R. In silico analysis of miRNA-mediated gene regulation in OCA and OA genes. Cell Biochem Biophys. 2014;70(3):1923–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Purohit R. Role of ELA region in auto-activation of mutant KIT receptor: a molecular dynamics simulation insight. J Biomol Struct Dyn. 2014;32(7):1033–46. Scholar
  44. 44.
    Rajendran V, Purohit R, Sethumadhavan R. In silico investigation of molecular mechanism of laminopathy caused by a point mutation (R482W) in lamin A/C protein. Amino Acids. 2012;43(2):603–15. Scholar
  45. 45.
    Zloh M, Kirton SB. The benefits of in silico modeling to identify possible small-molecule drugs and their off-target interactions. Future Med Chem. 2018;10(4):423–32. Scholar
  46. 46.
    Martinez-Rosell G, Harvey MJ, De Fabritiis G. Molecular-simulation-driven fragment screening for the discovery of new CXCL12 inhibitors. J Chem Inf Model. 2018. Scholar
  47. 47.
    Xu Z, Yu Z, Nai S, Shi R, Tang Q, Zhang H, Ye L, Wang L, Hong Y. Structure-based design of competitive ligands to target Spon2 in gastric cancer: an integration of molecular modeling and in vitro assay. Bioorg Chem. 2017;74:115–21. Scholar
  48. 48.
    Honegr J, Malinak D, Dolezal R, Soukup O, Benkova M, Hroch L, Benek O, Janockova J, Kuca K, Prymula R. Rational design of novel TLR4 ligands by in silico screening and their functional and structural characterization in vitro. Eur J Med Chem. 2018;146:38–46. Scholar
  49. 49.
    Levell JR, Caferro T, Chenail G, Dix I, Dooley J, Firestone B, Fortin PD, Giraldes J, Gould T, Growney JD, Jones MD, Kulathila R, Lin F, Liu G, Mueller A, van der Plas S, Slocum K, Smith T, Terranova R, Touré BB, Tyagi V, Wagner T, Xie X, Xu M, Yang FS, Zhou LX, Pagliarini R, Cho YS. Optimization of 3-pyrimidin-4-yl-oxazolidin-2-ones as allosteric and mutant specific inhibitors of IDH1. ACS Med Chem Lett. 2016;8(2):151–6. Scholar
  50. 50.
    Deng G, Shen J, Yin M, McManus J, Mathieu M, Gee P, He T, Shi C, Bedel O, McLean LR, Le-Strat F, Zhang Y, Marquette JP, Gao Q, Zhang B, Rak A, Hoffmann D, Rooney E, Vassort A, Englaro W, Li Y, Patel V, Adrian F, Gross S, Wiederschain D, Cheng H, Licht S. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule. J Biol Chem. 2015;290(2):762–74. Scholar
  51. 51.
    O’Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR. Open Babel: an open chemical toolbox. J Cheminform. 2011;3:33. Scholar
  52. 52.
    Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res. 2000;28(1):235–42.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinform. 2008;9:40. Scholar
  54. 54.
    Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER suite: protein structure and function prediction. Nat Methods. 2015;12(1):7–8. Scholar
  55. 55.
    Wu S, Zhang Y. MUSTER: improving protein sequence profile–profile alignments by using multiple sources of structure information. Proteins. 2008;72(2):547–56. Scholar
  56. 56.
    Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem. 2010;31:455–61.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo JC, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RL, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N. isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma. Cancer Discov. 2016;6(7):727–39. Scholar
  58. 58.
    De Wolf K, Rottey S, Vermaelen K, Decaestecker K, Sundahl N, De Lobel L, Goetghebeur E, De Meerleer G, Lumen N, Fonteyne V, De Maeseneer D, Ost P. Combined high dose radiation and pazopanib in metastatic renal cell carcinoma: a phase I dose escalation trial. Radiat Oncol. 2017;12(1):157. Scholar
  59. 59.
    Chellappan DK, Chellian J, Ng ZY, Sim YJ, Theng CW, Ling J, Wong M, Foo JH, Yang GJ, Hang LY, Nathan S, Singh Y, Gupta G. The role of pazopanib on tumour angiogenesis and in the management of cancers: a review. Biomed Pharmacother. 2017;96:768–81. Scholar
  60. 60.
    Zhang CX, Zhao WY, Liu L, et al. A nanostructure of functional targeting epirubicin liposomes dually modified with aminophenyl glucose and cyclic pentapeptide used for brain glioblastoma treatment. Oncotarget. 2015;6(32):32681–700.PubMedPubMedCentralGoogle Scholar
  61. 61.
    Zhou S, Zhang T, Peng B, et al. Targeted delivery of epirubicin to tumor-associated macrophages by sialic acid-cholesterol conjugate modified liposomes with improved antitumor activity. Int J Pharm. 2017;523(1):203–16.CrossRefPubMedGoogle Scholar
  62. 62.
    Charak S, Jangir DK, Tyagi G, Mehrotra R. Interaction studies of epirubicin with DNA using spectroscopic techniques. J Mol Struct. 2011;1000:150–4.CrossRefGoogle Scholar
  63. 63.
    Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.CrossRefPubMedGoogle Scholar
  64. 64.
    Rabbani A, Finn RM, Ausió J. The anthracycline antibiotics: antitumor drugs that alter chromatin structure. Bioessays. 2005;27:50–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Szuławska A, Czyz M. Molecular mechanisms of anthracyclines action. Postępy Hig Med Dośw. 2006;60:78–100.Google Scholar
  66. 66.
    Kmiecik SW, Krzyścik MA, Filip-Psurska B, Wietrzyk J, Boratyński J, Goszczyński TM. Methotrexate and epirubicin conjugates as potential antitumor drugs. Postepy Hig Med Dosw (Online). 2017;71:618–23.CrossRefPubMedGoogle Scholar
  67. 67.
    Qiao J-B, Jang Y, Fan Q-Q, Chang S-H, Xing L, Cui P-F, He Y-J, Lee S, Hwang S, Cho M-H, Jiang H-L. Aerosol delivery of biocompatible dihydroergotamine-loaded PLGA–PSPE polymeric micelles for efficient lung cancer therapy. Polym Chem. 2017;8(9):1540–54.CrossRefGoogle Scholar
  68. 68.
    Chang S, Lee AY, Yu K, Park J, Kim KP, Cho M. Dihydroergotamine tartrate induces lung cancer cell death through apoptosis and mitophagy. Chemotherapy. 2016;61(6):304–12.CrossRefPubMedGoogle Scholar
  69. 69.
    Miyamoto T, Kikushige Y, Yoshimoto A. Frontline treatment of AML in adults. Rinsho Ketsueki Jpn J Clin Hematol. 2017;58(10):1884–94.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Ezequiel Iván Juritz
    • 1
  • Juan Pablo Bascur
    • 1
  • Daniel Eduardo Almonacid
    • 1
    • 2
  • Fernando Danilo González-Nilo
    • 1
    • 3
  1. 1.Center for Bioinformatics and Integrative Biology, Facultad de Ciencias de la VidaUniversidad Andrés BelloSantiagoChile
  2. 2.uBiome, Inc.San FranciscoUSA
  3. 3.Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de CienciasUniversidad de ValparaísoValparaísoChile

Personalised recommendations